← Back to Patent Explorer
US4727018A Expired / Lapsed US ⏱️ 0.0 years remaining

Immunoregulation of transplantable tissue

Assignee: Australian National University
•
Filing: 1985-05-13
•
Granted: 1988-02-23
•
Expires: 2005-05-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Donor tissue is treated prior to implantation in a recipient with a compound from the class known as epipolythiodioxopiperazines in order to prevent graft rejection.

Inventors

  • 👤 Ronald D. Eichner
  • 👤 Arno Mullbacher

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 10:19
CPC Classifications
C; C07; C07D; C07D513/00; C07D513/02; C07D513/08; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/54; A61K31/55; A61P; A61P37/00; A61P37/02; A61P37/06; C12; C12N; C12N1/00; C12N1/14; C12N1/145; C12P; C12P17/00; C12P17/18; C12P17/185; C12R; C12R2001/00; C12R2001/645; C12R2001/66; C12R2001/68

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 138 words
A method of treating transplantable biological material to produce anti-phagocytic and immunomodulating properties comprising contacting said material with an effective amount of a compound of the general formula (1): ##STR4## alone or in association with one or more pharmaceutically acceptable carriers or diluents wherein R o and R 1 are radicals selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy and acyloxy; R 2 and R 3 are radicals separately selected from the group consisting of hydrogen and alkyl; or together, represent a radical of the general formula (2): ##STR5## wherein R 5 , R 6 , R 7 , R 8 and R 9 are radicals separately selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, sulfate, and halogen; or R 2 and R 3 together, represent a radical of the general formula (3): ##STR6##
Claim 2
Independent Claim 138 words
A method of treating transplantable biological material to produce anti-phagocytic and immunomodulating properties comprising contacting said material with an effective amount of a compound of the general formula (1): ##STR4## alone or in association with one or more pharmaceutically acceptable carriers or diluents wherein R o and R 1 are radicals selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy and acyloxy; R 2 and R 3 are radicals separately selected from the group consisting of hydrogen and alkyl; or together, represent a radical of the general formula (2): ##STR5## wherein R 5 , R 6 , R 7 , R 8 and R 9 are radicals separately selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, sulfate, and halogen; or R 2 and R 3 together, represent a radical of the general formula (3): ##STR6##
Claim 3
Independent Claim 45 words
A method of treating biological material for transplantation to a recipient, said method comprising incubating said material prior to transplantation, alone or in association with one or more pharmaceutically acceptable carrier or diluents, with an effective amount of a compound of the general formula (1).
Claim 4
Independent Claim 45 words
A method of treating biological material for transplantation to a recipient, said method comprising incubating said material prior to transplantation, alone or in association with one or more pharmaceutically acceptable carrier or diluents, with an effective amount of a compound of the general formula (1).
Claim 5
Dependent Claim 45 words
A method according to claim 2, said method comprising incubating said material prior to transplantation in the presence of a compound selected from the group consisting of gliotoxin, gliotoxin-tri-sulfide, gliotoxin-tetra-sulfide, sporidesmin, 1,4-dimethyl-3,6-epidithio-2,5-dioxopiperazine and dehydrogliotoxin, or derivatives thereof as described in general formulas 2 and 3.
Claim 6
Dependent Claim 42 words
A method according to claim 1, comprising incubating said material in the presence of a compound selected from the group consisting of gliotoxin, gliotoxin-tri-sulfide, gliotoxin-tetra-sulfide, sporidesmin, 1,4-dimethyl-3, 6-epidithio-2, 5-dioxopiperazine and dehydrogliotoxin, or derivatives thereof as described in general formulas 2 and 3.

References Cited (Backward Citations)

US3562253A Cited
CA1106303A Cited
US4117118A Cited
US4215199A Cited
EP0034567A2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-02-22 1991-08-24 1992-02-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-02-22 1995-08-24 1996-02-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-02-22 1999-08-24 2000-02-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag